Skip to main content

Invitrogen to Purchase Molecular Probes for $325M

NEW YORK, July 2 - Carlsbad, Calif.-based Invitrogen today announced the purchase of privately-held Molecular Probes of Eugene, Ore., in a $325 million cash transaction expected to close in the third quarter.


The acquisition brings together Invitrogen, a genomic research reagents, software and service provider with 28-year-old Molecular Probes, a provider of fluorescence-based technologies. With a market capitalization of nearly $2 billion, Invitrogen reported revenues of $181 million for the third quarter ending March 31.


Molecular Probes, founded in 1975, had revenues of $56 million in 2002, Invitrogen said.


With the sale, Invitrogen is aiming to position itself in the drug discovery and development sector, Greg Lucier, the company's CEO said in a statement.


The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.